An announcement from Aptose Biosciences ( (TSE:APS) ) is now available.
Aptose Biosciences has reported its year-end 2024 results and highlighted significant advancements in its tuspetinib-based triple drug therapy for AML. The ongoing TUSCANY clinical trial has shown promising results, achieving complete remissions in difficult-to-treat AML patients. The company has also signed a debt conversion agreement with Hanmi Pharmaceutical and entered a cooperative research agreement with the National Cancer Institute to further develop tuspetinib. These developments are expected to enhance Aptose’s position in the oncology market and provide additional funding for its clinical programs.
More about Aptose Biosciences
Aptose Biosciences Inc. is a clinical-stage precision oncology company focused on developing innovative therapies for the treatment of cancer. The company is particularly involved in creating a tuspetinib-based triple drug frontline therapy for patients with newly diagnosed acute myeloid leukemia (AML).
YTD Price Performance: -45.27%
Average Trading Volume: 221,333
Technical Sentiment Signal: Strong Buy
Current Market Cap: $8.13M
For a thorough assessment of APS stock, go to TipRanks’ Stock Analysis page.